Trending Conversations at CPHI Japan 2026

CPHI Japan 2026 highlighted a biopharma landscape defined by accelerating innovation, increasing pipeline complexity, and a growing emphasis on global execution.

From record-breaking approvals and China’s expanding role in novel therapeutics to the rapid rise of biologics, obesity therapies, and cross-border licensing partnerships, the conversations across the event reflected an industry moving faster, and becoming more interconnected, than ever before.

Representing Tanner Pharma Group’s Clinical Trial Solutions team on site, Roberta Blaj and Rory Williams engaged with leaders across the global pharmaceutical ecosystem to explore the trends shaping the next generation of development and commercialization strategies.

This recap captures the key themes emerging from those discussions, including the operational challenges and opportunities created by evolving R&D pipelines, increasingly sophisticated therapies, and the growing need for scalable global access models.

Across every conversation, one message was clear: success in today’s market requires more than innovation alone. It depends on the ability to operationalize quickly, navigate complexity confidently, and execute globally with precision.

At Tanner Pharma Group, we help biopharmaceutical companies translate strategy into action through flexible Clinical Trial Solutions and global access pathways designed to support execution at every stage.